ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.25% | -0.75% | 5.47% | 9.88% | 16.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.25% | -0.75% | 5.47% | 9.88% | 16.97% |
| Cost of Revenue | -14.69% | 1.49% | 12.22% | 25.89% | 34.85% |
| Gross Profit | 8.57% | -2.84% | -0.45% | -3.33% | 2.86% |
| SG&A Expenses | -4.73% | 4.68% | 4.86% | 0.59% | 0.81% |
| Depreciation & Amortization | -36.16% | -30.47% | -33.27% | -35.01% | -33.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.91% | 3.37% | 4.40% | -6.35% | -17.41% |
| Operating Income | 16.03% | -10.97% | -2.69% | 24.73% | 45.39% |
| Income Before Tax | -14.69% | -215.26% | -76.69% | -34.31% | -1.08% |
| Income Tax Expenses | -50.02% | -148.97% | -157.79% | -142.68% | -113.61% |
| Earnings from Continuing Operations | -11.18% | -225.67% | -70.17% | -28.00% | 3.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.18% | -225.67% | -70.17% | -28.00% | 3.94% |
| EBIT | 16.03% | -10.97% | -2.69% | 24.73% | 45.39% |
| EBITDA | 1.89% | -42.69% | -24.99% | 24.99% | 54.54% |
| EPS Basic | 9.31% | -179.69% | -59.02% | -20.62% | 8.79% |
| Normalized Basic EPS | 21.72% | -4.70% | -1.78% | 26.33% | 47.19% |
| EPS Diluted | 9.31% | -179.69% | -59.02% | -20.62% | 8.79% |
| Normalized Diluted EPS | 21.72% | -4.70% | -1.78% | 26.33% | 47.19% |
| Average Basic Shares Outstanding | 30.59% | 13.70% | 7.63% | 4.73% | 2.97% |
| Average Diluted Shares Outstanding | 30.59% | 13.70% | 7.63% | 4.73% | 2.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |